Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
Top Cited Papers
Open Access
- 24 June 2020
- journal article
- research article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 79 (9), 1243-1249
- https://doi.org/10.1136/annrheumdis-2019-216863
Abstract
Objectives Evaluation of rituximab and glucocorticoids as therapy to induce remission after relapse in ANCA-associated vasculitis (AAV) in a prospective observational cohort of patients enrolled into the induction phase of the RITAZAREM trial. Methods Patients relapsing with granulomatosis with polyangiitis or microscopic polyangiitis were prospectively enrolled and received remission-induction therapy with rituximab (4×375 mg/m2) and a higher or lower dose glucocorticoid regimen, depending on physician choice: reducing from either 1 mg/kg/day or 0.5 mg/kg/day to 10 mg/day by 4 months. Patients in this cohort achieving remission were subsequently randomised to receive one of two regimens to prevent relapse. Results 188 patients were studied: 95/188 (51%) men, median age 59 years (range 19–89), prior disease duration 5.0 years (range 0.4–34.5). 149/188 (79%) had previously received cyclophosphamide and 67/188 (36%) rituximab. 119/188 (63%) of relapses had at least one major disease activity item, and 54/188 (29%) received the higher dose glucocorticoid regimen. 171/188 (90%) patients achieved remission by 4 months. Only six patients (3.2% of the study population) did not achieve disease control at month 4. Four patients died in the induction phase due to pneumonia (2), cerebrovascular accident (1), and active vasculitis (1). 41 severe adverse events occurred in 27 patients, including 13 severe infections. Conclusions This large prospective cohort of patients with relapsing AAV treated with rituximab in conjunction with glucocorticoids demonstrated a high level of efficacy for the reinduction of remission in patients with AAV who have relapsed, with a similar safety profile to previous studies.Keywords
Funding Information
- Research Committee on Intractable Vasculitides; The Ministry of Health, Labour and Welfare of Japan.
- National Center for Research Resources (U54 RR019497)
- Roche/Genentech (MA28150)
- Versus Arthritis (18706)
This publication has 17 references indexed in Scilit:
- Pathogenesis of Antineutrophil Cytoplasmic Autoantibody–Associated Small-Vessel VasculitisAnnual review of pathology, 2013
- 2012 Revised International Chapel Hill Consensus Conference Nomenclature of VasculitidesArthritis & Rheumatism, 2012
- Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): Ten‐year experience at a single centerArthritis & Rheumatism, 2012
- Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody–associated vasculitis: A meta‐analysisArthritis Care & Research, 2010
- Rituximab versus Cyclophosphamide in ANCA-Associated Renal VasculitisThe New England Journal of Medicine, 2010
- Rituximab versus Cyclophosphamide for ANCA-Associated VasculitisThe New England Journal of Medicine, 2010
- A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody–associated vasculitisArthritis & Rheumatism, 2009
- Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic Antibody—Associated VasculitisAnnals of Internal Medicine, 2009
- Etanercept plus Standard Therapy for Wegener's GranulomatosisThe New England Journal of Medicine, 2005
- Long-term follow-up study of periarteritis nodosaAmerican Journal Of Medicine, 1967